ES2124702T3 - Usos terapeuticos de compuestos que se unen a actina. - Google Patents

Usos terapeuticos de compuestos que se unen a actina.

Info

Publication number
ES2124702T3
ES2124702T3 ES91908685T ES91908685T ES2124702T3 ES 2124702 T3 ES2124702 T3 ES 2124702T3 ES 91908685 T ES91908685 T ES 91908685T ES 91908685 T ES91908685 T ES 91908685T ES 2124702 T3 ES2124702 T3 ES 2124702T3
Authority
ES
Spain
Prior art keywords
actina
therapeutic uses
compounds binding
modified
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91908685T
Other languages
English (en)
Inventor
Thomas P Stossel
Stuart E Lind
Paul A Janmey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of ES2124702T3 publication Critical patent/ES2124702T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)

Abstract

SE DESCRIBE UN METODO PARA REDUCIR LA CONCENTRACION DE ACTINA LIBRE EN EL PLASMA DE UN ANIMAL QUE COMPRENDE LA ADMINISTRACION DE PROTEINAS ACTINA-LIGANTES MODIFICADAS Y NATURALES Y, ESPECIALMENTE, LA ADMINISTRACION DE REGIONES ACTINA-LIGANTES MODIFICADAS Y NATURALES DE GELSOLINA. TAMBIEN SE DESCRIBEN METODOS DE DIAGNOSTICO PARA LA IDENTIFICACION DE ANIMALES QUE NECESITEN DICHO TRATAMIENTO.
ES91908685T 1990-04-11 1991-04-11 Usos terapeuticos de compuestos que se unen a actina. Expired - Lifetime ES2124702T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50721490A 1990-04-11 1990-04-11
PCT/US1991/002553 WO1991015770A1 (en) 1990-04-11 1991-04-11 Therapeutic uses of actin-binding compounds

Publications (1)

Publication Number Publication Date
ES2124702T3 true ES2124702T3 (es) 1999-02-16

Family

ID=24017703

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91908685T Expired - Lifetime ES2124702T3 (es) 1990-04-11 1991-04-11 Usos terapeuticos de compuestos que se unen a actina.

Country Status (10)

Country Link
US (2) US5260224A (es)
EP (1) EP0526544B1 (es)
JP (2) JP3616392B2 (es)
AT (1) ATE171625T1 (es)
AU (1) AU663050B2 (es)
CA (1) CA2080462C (es)
DE (1) DE69130289T2 (es)
DK (1) DK0526544T3 (es)
ES (1) ES2124702T3 (es)
WO (1) WO1991015770A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0526544T3 (da) * 1990-04-11 1999-06-21 Brigham & Womens Hospital Terapeutiske anvendelser af actinbindende forbindelser
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
WO1995024207A1 (en) * 1994-03-11 1995-09-14 Merck & Co., Inc. Composition for the treatment of lung disease
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
USRE38392E1 (en) 1996-01-30 2004-01-20 Baylor College Of Medicine Method for identifying metastatic sequences
PT941108E (pt) 1996-12-04 2003-01-31 Renovo Ltd Cicatrizacao de feridas e tratamento da fibrose
JP2002511748A (ja) * 1997-05-19 2002-04-16 カイロン コーポレイション アポトーシス誘導性ゲルゾリン配列
CA2308565A1 (en) 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
US6545139B1 (en) 1998-03-13 2003-04-08 Baylor College Of Medicine DNA sequence encoding the p99 gene and kits for the detection of neoplasia
US6403766B1 (en) 1999-10-15 2002-06-11 Cornell Research Foundation, Inc. Human actin regulatory proteins and methods for detection, diagnosis and treatment of different stages of carcinogenesis
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
CA2456843A1 (en) * 2001-08-14 2003-02-27 Statens Serum Institut A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine
US7462491B2 (en) * 2002-01-31 2008-12-09 Baylor College Of Medicine Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin
US20030224464A1 (en) * 2002-01-31 2003-12-04 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
WO2003088811A2 (en) * 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
US7301020B2 (en) * 2003-06-19 2007-11-27 Wisconsin Alumni Research Foundation Macrolide analogs and methods for identifying same
DK1694342T3 (da) * 2003-11-12 2021-02-08 Univ Pennsylvania Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
EP1755661B1 (en) * 2004-05-12 2014-03-12 The Brigham And Women's Hospital, Inc. Gelsolin for use in treating infections
US20060030539A1 (en) * 2004-08-06 2006-02-09 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
ES2641879T3 (es) 2006-03-15 2017-11-14 The Brigham And Women's Hospital, Inc. Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias
HUE035980T2 (hu) 2006-03-15 2018-06-28 Brigham & Womens Hospital Inc Gelzolin alkalmazása szklerózis multiplex kezelésére és neurológiai betegségek diagnosztizálására
CA2713977A1 (en) * 2007-02-15 2008-08-21 National Jewish Medical And Research Center Methods and compositions for the disruption of biofilms
DK2250280T3 (en) * 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1969388A (en) * 1987-06-19 1989-01-19 Syracuse University Cytochalasin purification methods and compositions
DK0526544T3 (da) * 1990-04-11 1999-06-21 Brigham & Womens Hospital Terapeutiske anvendelser af actinbindende forbindelser
JPH09315440A (ja) * 1996-05-29 1997-12-09 Mitsui Petrochem Ind Ltd ラップフィルム収納箱

Also Published As

Publication number Publication date
CA2080462A1 (en) 1991-10-12
ATE171625T1 (de) 1998-10-15
JPH05506034A (ja) 1993-09-02
DK0526544T3 (da) 1999-06-21
EP0526544A1 (en) 1993-02-10
EP0526544B1 (en) 1998-09-30
EP0526544A4 (en) 1993-08-11
WO1991015770A1 (en) 1991-10-17
CA2080462C (en) 2004-10-26
AU663050B2 (en) 1995-09-28
US5508265A (en) 1996-04-16
DE69130289T2 (de) 1999-06-02
AU7751691A (en) 1991-10-30
DE69130289D1 (de) 1998-11-05
US5260224A (en) 1993-11-09
JP2005041881A (ja) 2005-02-17
JP3616392B2 (ja) 2005-02-02

Similar Documents

Publication Publication Date Title
ES2124702T3 (es) Usos terapeuticos de compuestos que se unen a actina.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
DK0731699T3 (da) Fremgangsmåde til reduktion af legemsfedt i dyr ved indgivelse af konjugeret linolsyre
ATE213390T1 (de) Wirkstoff zur erhöhung der produktion und der zucht von tieren in der geflügelindustrie
DE69410630D1 (de) Vorrichtung zur frühembryonalen in ovo injektion
AU7814498A (en) Multivalent (in ovo) avian vaccine
DE69801660D1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
ATE225125T1 (de) Lösung zur konservierung von organen oder geweben oder teilen davon aus menschen oder tieren
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
ATE90181T1 (de) Verwendung von pankreatin enthaltendem futter oder praemix fuer rennpferde und rennkamele.
EA199800866A1 (ru) Способ снятия боли
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ES2085199B1 (es) Un procedimiento para la preparacion de una formulacion depot.
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ES2138053T3 (es) Formulacion insecticida solida.
MX9206135A (es) Metodos
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
BR9612549A (pt) Método para tratamento de agressão excessiva
RU94003799A (ru) Способ лечения псороптозов животных
BR9406372A (pt) Processo para aperfeiçoar a produtividade de animais ruminantes e preparação veterinária

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19940404

FG2A Definitive protection

Ref document number: 526544

Country of ref document: ES